The development of physiologically relevant human models for neurological diseases remains a challenge for pre-clinical drug discovery. With the emergence of human induced pluripotent stem cell (iPSC)-technology, it is now possible to design and manufacture cell types that are critical players in neural disease pathogenesis, such as neurons, astrocytes and microglia. These iPSC-derivatives retain their patient-specific genetic backgrounds and demonstrate clinically relevant phenotypes.
They, therefore, can serve as human in vitro platforms to accelerate the drug development pipeline. A first challenge to implementing iPSCs for drug discovery is the reproducible and large-scale generation of high quality and functional differentiated derivatives. During this webinar we will discuss the advantages and challenges of manufacturing and co-culturing iPSC-derived neuronal models for disease modeling, assay development and drug testing purposes.
The benefits of using iPSC-derived neuronal models for drug discovery
Key considerations for the large-scale generation of functional human iPSC-derived neuronal cells
Insights into co-culturing possibilities of iPSC-derived neurons, astrocytes and microglia.